Phase 1 Results in Healthy Volunteers Show Potential for Subcutaneous Administration of VRDN-003, a Half-life Extended Full Antagonist Antibody to IGF-1R, for Thyroid Eye Disease (TED). Annual Meeting of The European Society of Opthalmic Plastic and Reconstructive Surgery September 2024.